Specific stability indicating spectrofluorimetric method for determination of ledipasvir in the presence of its confirmed degradation products; application in human plasma

被引:8
作者
Ali, Ramadan [1 ]
Marzouk, Adel A. [2 ]
Abdelhameid, Reda A. [3 ]
Omar, Mahmoud A. [4 ]
机构
[1] Al Azhar Univ, Fac Pharm, Analyt Pharmaceut Chem Dept, Assiut 71524, Egypt
[2] Al Azhar Univ, Fac Pharm, Pharmaceut Chem Dept, Assiut, Egypt
[3] Al Azhar Univ, Assiut Branch, Fac Pharm, Pharmacognosy Dept, Assiut, Egypt
[4] Menia Univ, Fac Pharm, Analyt Chem Dept, Al Minya, Egypt
关键词
Ledipasvir; Polyoxyethylene; 50; stearate; Spectrofluorimetric determination; Human plasma; HEPATITIS-C VIRUS; PHARMACEUTICAL-PREPARATIONS; SPECTROPHOTOMETRIC METHODS; MS/MS METHOD; SOFOSBUVIR; TABLET; COMBINATION; INFECTION;
D O I
10.1016/j.saa.2018.05.044
中图分类号
O433 [光谱学];
学科分类号
0703 ; 070302 ;
摘要
A rapid and specific spectrofluorimetric method with higher sensitivity was developed for determination of ledipasvir (LDS) in tablets and human plasma. The proposed method relies on hydrogen bonding formations between the hydroxyl groups of polyoxyethylene 50 stearate and LDS, causing significant enhancement of its native fluorescence. The fluorescence intensity was measured at 430 nm after excitation at 340 nm. The fluorescence concentration plot was rectilinear over the range 1-400 ng mL(-1) with detection and quantification limits of 0.25 and 1.10 ng mL(-1), respectively. The high sensitivity of the proposed method permits its application for ledipasvir determinations in real human plasma even in the presence of co-administered drugs sofosbuvir and ribavirin. Moreover, the proposed method was further extended to stability studies of ledipasvir after exposure to different forced degradation conditions according to ICH guidelines, along with the structural elucidation of its degradation products utilizing IR and Mass spectra. A proposal for the degradation pathways was presented. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:50 / 57
页数:8
相关论文
共 32 条
[1]   Spectrophotometric Methods for Simultaneous Determination of Sofosbuvir and Ledipasvir (HARVONI Tablet): Comparative Study with Two Generic Products [J].
Abo-Talib, Nisreen F. ;
El-Ghobashy, Mohamed R. ;
Tammam, Marwa H. .
JOURNAL OF AOAC INTERNATIONAL, 2017, 100 (04) :976-984
[2]  
[Anonymous], 2005, ICH HARMONIZED TRIPA
[3]  
[Anonymous], 2001, Guidance for industry, bioanalytical method validation
[4]  
[Anonymous], 2016, ANAL CHEM LETT, DOI DOI 10.1080/22297928.2016.1265468
[5]   A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma [J].
Ariaudo, Alessandra ;
Favata, Fabio ;
De Nicolo, Amedeo ;
Simiele, Marco ;
Paglietti, Luca ;
Boglione, Lucio ;
Cardellino, Chiara Simona ;
Carcieri, Chiara ;
Di Perri, Giovanni ;
D'Avolio, Antonio .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2016, 125 :369-375
[6]   Enhancement of the sensitivity of valacyclovir and acyclovir for their spectrofluorimetric determination in human plasma [J].
Derayea, Sayed M. ;
Omar, Mahmoud A. ;
Mostafa, Islam M. ;
Hammad, Mohamed A. .
RSC ADVANCES, 2015, 5 (96) :78920-78926
[8]   Chromatographic analysis of ledipasvir and sofosbuvir: New treatment for chronic hepatitis C infection with application to human plasma [J].
Farid, Nehal F. ;
Abdelwahab, Nada S. .
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2017, 40 (07) :327-332
[9]   Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study [J].
Feld, Jordan J. ;
Ramji, Alnoor ;
Shafran, Stephen D. ;
Willems, Bernard ;
Marotta, Paul ;
Huchet, Emmanuelle ;
Vachon, Marie-Louise ;
Svarovskaia, Evguenia S. ;
Huang, K. C. ;
Hyland, Robert H. ;
Yun, Chohee ;
Massetto, Benedetta ;
Brainard, Diana M. ;
McHutchison, John G. ;
Tam, Edward ;
Bailey, Robert ;
Cooper, Curtis ;
Yoshida, Eric M. ;
Greenbloom, Susan ;
Elkhashab, Magdy ;
Borgia, Sergio ;
Swain, Mark G. .
CLINICAL INFECTIOUS DISEASES, 2017, 65 (01) :13-19
[10]   Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C [J].
German, Polina ;
Mathias, Anita ;
Brainard, Diana ;
Kearney, Brian P. .
CLINICAL PHARMACOKINETICS, 2016, 55 (11) :1337-1351